We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close review.
What intellectual property is, how you can protect it, and which of copyright, patents, design right and trade marks applies to your work.
As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review.
You must tell DVLA if you have muscular dystrophy - download the correct form to let them know.
We are now implementing the recommendations of the Keep Britain Working independent review of the role of employers in health and disability, published 5 November 2025. This page brings together information about the review and progress since publication.
As the cold weather sets in and coughs and colds become more common, the MHRA is reminding people that small, everyday choices can make a big difference to winter wellbeing.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).